Oncology

The FDA has approved second-line axicabtagene ciloleucel as a treatment for adult patients with large B-cell lymphoma following frontline chemoimmunotherapy.

Review top news and interview highlights from the week ending April 1, 2022.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Allogene’s clinical hold on their AlloCAR T candidates was previously lifted in January 2022.

Research presented at the EBMT meeting suggests cell expansion may be a good biomarker of both response and outcomes.

Review top news and interview highlights from the week ending March 25, 2022.

A prespecified interim analysis from the phase 3 TRANSFORM study showed an event-free survival benefit with the second-line therapy.

A2 Biotherapeutics is developing CEA- and MSLN- targeted Tmod CAR T-cell therapies.

The professors and researchers from The University of Texas at Austin discussed new findings of Cas9 structure and mechanisms.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Seven patients from the trial continued to be followed-up as of the data cut-off date.

Viral vectors have become the most common method for delivering gene therapy; however, pre-existing humoral immunogenicity can potentially render a gene therapy ineffective.

Olaparib is now the first early-line therapy targeting BRCA-mutations in breast cancer.

Half the patients in the high-dose cohort of a phase 1a/2b trial achieved complete responses.

Review top news and interview highlights from the week ending March 18, 2022.

The draft guidance from the Center for Biologics Evaluation and Research outlines safety considerations throughout the clinical development program timeline.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

WU-CART-007 is the first clinical-stage allogeneic CAR therapy for T-cell malignancies in the US.

The clinical professor of medicine, Helen Diller Family Comprehensive Cancer Center, UCSF, discussed potential effects of cilta-cel's approval.

Review top news and interview highlights from the week ending March 11, 2022.

The first patient was dosed in the phase 1/2a trial earlier in March 2022.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The chief of the lymphoma division and oncologist at Levine Cancer Institute discussed the impact of CAR T-cell therapies in patients with lymphoma.

Jennifer Buell, PhD, president and chief executive officer, MiNK Therapeutics, discussed the company’s iNKT cell platform.

Oliver Van Oekelen, MD, MSc, resident and PhD student, Icahn School of Medicine, Mount Sinai, discussed findings from a retrospective study.